Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-Specific Mutant Peptide Antigen (Neoantigen)
- Target
- Neoantigen
- Molecular classification
- Peptide, Antigen
01
Overview
Tumor-specific mutant peptide antigens (“neoantigens”) are uniquely mutated short peptides generated by genomic alterations exclusive to tumors. They serve as potent targets for personalized immunotherapies due to their high specificity and ability to elicit robust anti-tumoral immune responses without affecting healthy tissue.
- Other names
- NeoepitopeTumor-specific antigen
02
Mechanism of action
Neoantigens are presented on MHC molecules and recognized by T cells, leading to targeted killing of tumor cells. Personalized vaccines prime the immune system against these neoantigens. Adoptive cell therapies utilize T cells engineered to target specific neoepitopes. Immune checkpoint blockade efficacy is enhanced in tumors with high neoantigen load.
03
Biological functions
Antigen presentationT-cell activationImmune responseTarget for cytotoxic T lymphocytes (CTLs)
04
Disease associations
CancerTarget for immunotherapy
05
Safety considerations
Off-target effects (though minimized due to specificity)Immune-related adverse events (irAEs)Tumor immune escape
06
Interacting drugs
Personalized cancer vaccines
2 more in the full profile.
07
Biomarkers
Mutational burdenNeoantigen loadT-cell infiltrationMHC expression
Beyond the preview
Go deeper on Tumor-Specific Mutant Peptide Antigen (Neoantigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Specific Mutant Peptide Antigen (Neoantigen).